Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

MOUNTAIN VIEW, Calif., Oct. 27, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report financial results for the quarter ended September 30, 2011, on Monday, November 7, 2011, following the close of the U.S. financial markets.  On Monday, November 7, at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time, the Company will host an investor conference call and live webcast to provide a company update, as well as to discuss the financial results.  The conference call, live webcast and archived replay are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.  Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PVXTMU3TM.

To access the live conference call via phone, dial 888-713-4199.  International callers may access the live call by dialing +1-617-213-4861.  The reference number to enter the call is 78230377.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or +1-617-801-6888 for international callers.  The reference number for the replay of the call is 50703911.  A replay of the call will be available for two weeks following the event.

About Alexza Pharmaceuticals, Inc.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today ... diagnostic platform during a special event at the company,s ... , on September 5, 2014. The event, which will ... the ApolloDx website, www.apollodx.com .    ... testing," said Jared Bauer , Co-Founder and Managing ...
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Inc. (Nasdaq: BNVI ), a pharmaceutical company focused ... health and cancer, today announced that it had received the ... Guidance meeting that took place on November 8, 2010. In ... clinical development plan. "We had a very ...
... U.S.A. Inc., (TRL) announced today that it has entered into ... development of novel protein therapies for autoimmune diseases based on ... Anaphore will generate novel trivalent proteins called Atrimers ... inhibit targets of interest . The partnership will focus ...
Cached Medicine Technology:Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 2Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 3Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 4Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders 2Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders 3
(Date:8/20/2014)... of brain cells that act as a "sleep switch" ... and staying asleep, a new study suggests. In ... often results in nighttime confusion and wandering, according to ... Rush Memory and Aging Project, which includes nearly 1,000 ... followed until death, at which point their brains are ...
(Date:8/20/2014)... By Kathleen Doheny ... -- Breast reconstruction after a mastectomy has long been an ... percent of women choose it. "The most common reasons ... important, they weren,t interested in more surgery or they were ... Morrow, chief of breast surgery at Memorial Sloan Kettering Cancer ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... With 3943.8% growth, Connexion Point ranks number ... fastest growing companies. The Inc. 500 ranks Connexion Point 12th, ... Point is the #1 fastest growing company in Utah. , ... and its clients include four of the top 10 health ... and has offices and contact centers in Salt Lake City, ...
(Date:8/20/2014)... YORK, NY (August 20, 2014) Research from Columbia ... critical role in stomach cancer growth and that blocking ... an effective treatment for the disease. The study was ... in collaboration with Duan Chen, MD, PhD, in Norway ... Translational Medicine . , "Scientists have long observed that ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... the pioneer and largest provider of retail-based health care in the ... test at its 23 locations inside select CVS/pharmacy stores in the ... in partnership with Rapid Pathogen Screening, Inc (RPS). MinuteClinic hopes ... clinic locations in 25 states. , , The ...
... , ENCINITAS, Calif., Aug. 11 DRJ Group ... today announced a new awareness and fundraising initiative with the Arthritis ... portion of each Stopain purchase to support the Foundation,s mission to ... is issuing a just-released video - Stop Pain. Start Dancing ...
... , , NEW YORK, Aug. 11 ... bank has acquired Park Avenue Fertility, located in the heart of ... bank will be able to offer local services in both Los ... reproductive medicine. , , "California Cryobank has ...
... , , NEW YORK, Aug. ... a contract by ValueOptions(R), a behavioral health care company headquartered ... services for ValueOptions(R) at risk Plans, which cover approximately 1.5 ... Medicaid members that have other healthcare coverage, and recover overpayments ...
... , , , ... that many claim to value personal responsibility, yet the lack of ... less responsible than they take credit for being. , , ... While the decisions made by those running large corporations influenced the ...
... , TROY, Mich., Aug. 11 CareTech Solutions, Inc. ... inform a tion t echnology (IT) and ... provider for hospitals and health systems nationwide, announced today it has signed a three-year ... e gri s -health.com ), based in Oklahoma. , ...
Cached Medicine News:Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 2Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 3Health News:Photo: Stopain and the Arthritis Foundation Join Forces to Promote the Benefits of Staying Active 2Health News:Nation's Leading Sperm Bank Opens Branch in New York City 2Health News:ValueOptions(R) Awards Coordination of Benefits and Overpayment Services Contract to HMS 2Health News:Author Alison Stein Identifies Widespread Crisis in Personal Responsibility, Outlines Path to Solution in Reality 2Health News:CareTech Signs Three-Year Agreement to Provide Web Services to INTEGRIS Health's 13 Hospitals 2Health News:CareTech Signs Three-Year Agreement to Provide Web Services to INTEGRIS Health's 13 Hospitals 3
... Lipoprint System is a high resolution diagnostic test ... by other methods. The test procedure is simple ... hours. Any abnormal value is clearly flagged. A ... atherogenic, small dense LDL in red and the ...
... is the only control for ... patient synovial fluid samples performed ... is also an aid for ... indicate a pathological condition present ...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
... designed for point-of-care dipstick control. Its unique, ... problems and provides maximum portability ideal ... is the addition of creatinine and microalbumin. ... results for hCG for early pregnancy detection ...
Medicine Products: